Humana Files 8-K for Regulation FD Disclosure on Feb 5, 2024
Ticker: HUM · Form: 8-K · Filed: Feb 5, 2024 · CIK: 49071
| Field | Detail |
|---|---|
| Company | Humana Inc (HUM) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $6, $10 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-governance
TL;DR
**Humana just filed an 8-K for Regulation FD, expect new material info soon.**
AI Summary
Humana Inc. filed an 8-K on February 5, 2024, under Regulation FD Disclosure, indicating that they are making a public disclosure of material non-public information. This filing, while not detailing the specific information, signals that Humana is proactively sharing important news with investors. For shareholders, this means new information that could impact the stock price is being released, and they should look for subsequent announcements or details to understand the full implications.
Why It Matters
This filing signals that Humana Inc. is disclosing material information to the public, which could influence investor sentiment and the company's stock performance. Investors should anticipate further details to understand the nature of this disclosure.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing indicating a disclosure, not a specific event, so the immediate risk is low.
Analyst Insight
A smart investor would monitor Humana's news releases and SEC filings closely for the specific details of the Regulation FD disclosure, as this information could impact the stock's valuation.
Key Players & Entities
- Humana Inc. (company) — the registrant filing the 8-K
- February 5, 2024 (date) — date of earliest event reported and filing date
- Regulation FD Disclosure (other) — the item information for the 8-K
Forward-Looking Statements
- Humana will release specific details regarding the material non-public information disclosed under Regulation FD. (Humana Inc.) — high confidence, target: within 1-3 business days
FAQ
What is the purpose of Humana Inc.'s 8-K filing on February 5, 2024?
The purpose of Humana Inc.'s 8-K filing on February 5, 2024, is for 'Regulation FD Disclosure,' indicating they are making a public disclosure of material non-public information.
What is Humana Inc.'s trading symbol and on which exchange is its common stock registered?
Humana Inc.'s trading symbol is HUM, and its Common Stock is registered on the New York Stock Exchange.
What is the address of Humana Inc.'s principal executive offices?
The address of Humana Inc.'s principal executive offices is 500 West Main Street, Louisville, KY 40202.
What is the Commission File Number for Humana Inc.?
Humana Inc.'s Commission File Number is 1-5975.
Is Humana Inc. considered an emerging growth company according to this filing?
No, the filing indicates with an unchecked box that Humana Inc. is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 15 · Accepted 2024-02-05 07:00:57
Key Financial Figures
- $6 — change to the company's 2025 outlook of $6 to $10 in Adjusted Earnings Per Share (
- $10 — to the company's 2025 outlook of $6 to $10 in Adjusted Earnings Per Share (EPS) gr
Filing Documents
- hum-20240205.htm (8-K) — 30KB
- 0000049071-24-000009.txt ( ) — 153KB
- hum-20240205.xsd (EX-101.SCH) — 2KB
- hum-20240205_lab.xml (EX-101.LAB) — 24KB
- hum-20240205_pre.xml (EX-101.PRE) — 12KB
- hum-20240205_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On Wednesday, January 31, 2024, after the stock market closed, the Centers for Medicare and Medicaid Services (CMS) issued its preliminary 2025 Medicare Advantage and Part D payment rates and proposed policy changes (collectively, the Advance Notice). CMS has invited public comment on the Advance Notice before publishing final rates on April 1, 2024 (the Final Notice). In the Advance Notice, CMS estimates Medicare Advantage plans across the sector will, on average, experience a 0.16 percent decrease in benchmark funding based on proposals included therein. As indicated by CMS, its estimate excludes the impact of fee-for-service county rebasing/re-pricing since the related impact is dependent upon finalization of certain data, which will be available with the publication of the Final Notice. Based on Humana Inc.'s (the "company") preliminary analysis using the same factors included in CMS' estimate, the components of which are detailed on CMS' website, the company anticipates the proposals in the Advance Notice would result in a change to its benchmark funding that is approximately 160 basis points worse than its expectation of a flat rate environment. This difference is primarily due to the proposed effective growth rate restatements, which the company did not anticipate in light of the higher medical cost trends experienced across the industry, as well as the negative impact of CMS' proposed normalization factors. As part of its typical engagement with the agency, the company will provide actuarial data with respect to its concerns regarding these items. The company will continue to analyze the Advance Notice and will draw upon its program expertise to provide CMS formal commentary on the impact of the Advance Notice and the related impact upon Medicare beneficiaries' quality of care, affordability, and service to its members through the Medicare Advantage program. There is no change to the company's 2025 outlook of $6
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. HUMANA INC. BY: /s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer) Dated: February 5, 2024